The MarketWatch News Department was not involved in the creation of this content. -- New indications expand treatment options for appropriate children aged 2.5 years and older with Idiopathic Short ...
Sogroya is a long-acting form of somatropin. Somatropin is also called human growth hormone. Sogroya is made by attaching human growth hormone to a small protein that helps it stay in the body longer ...
The FDA expanded the indication of the long-acting growth hormone somapacitan (Sogroya) to include very young children with idiopathic short stature, short stature born small for gestational age, or ...
(RTTNews) - The FDA handed out a string of approvals in late February and early March, granting regulatory clearances across several therapeutic areas - from oncology and rare genetic disorders to ...
PLAINSBORO, N.J., Feb. 27, 2026 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya ® ...
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results